



(12) Translation of
european patent specification

(11) NO/EP 2297115 B1

NORWAY

(19) NO
(51) Int Cl.
C07D 405/12 (2006.01)
A61K 31/4709 (2006.01)
A61K 31/517 (2006.01)
A61P 29/00 (2006.01)
A61P 35/00 (2006.01)

Norwegian Industrial Property Office

(21)	Translation Published	2015.12.14
(80)	Date of The European Patent Office Publication of the Granted Patent	2015.07.22
(86)	European Application Nr.	09743783.4
(86)	European Filing Date	2009.05.08
(87)	The European Application's Publication Date	2011.03.23
(30)	Priority	2008.05.09, US, 118019
(84)	Designated Contracting States:	AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR
(73)	Proprietor	Hutchison Medipharma Enterprises Limited, Offshore Group Chambers P.O. Box CB-12751, Nassau, BS-Bahamas
(72)	Inventor	SU, Wei-Guo, Zhangjian High-Tech Park720 Cai Lun Road, Shanghai 510620, CN-Kina ZHANG, Weihai, Room 1703 Building 8 1599 Ding Xiang Road, PudongShanghai 510620, CN-Kina YAN, Xiaoqiang, 338 1115 Lane Xiu Yan Road, Nan HuiShanghai, CN-Kina CUI, Yumin, Room 701 Building 26 259 Tian Den Road, Shanghai 510620, CN-Kina REN, Yongxin, Zhangjian High-Tech Park720 Cai Lun Road, Shanghai 510620, CN-Kina DUAN, Jifeng, 20-902 888 Jin Xiu Road, PudongShanghai 510620, CN-Kina
(74)	Agent or Attorney	Oslo Patentkontor AS, Postboks 7007 Majorstua, 0306 OSLO, Norge

(54)	Title	DIALKOXYQUINAZOLINE DERIVATIVES AS KDR INHIBITORS
(56)	References Cited:	EP-A2- 1 265 874 WO-A1-02/30924 WO-A1-2005/063739 WO-A1-2009/036055 US-A1- 2007 208 056 US-A1- 2008 033 000 BOYER S J: "SMALL MOLECULE INHIBITORS OF KDR (VEGFR-2) KINASE: AN OVERVIEW OF STRUCTURE ACTIVITY RELATIONSHIPS", CURRENT TOPICS IN MEDICINAL CHEMISTRY, BENTHAM SCIENCE PUBLISHERS LTD, NETHERLANDS, vol. 2, no. 9, 1 September 2002 (2002-09-01), pages 973-1000, XP008033112, ISSN: 1568-0266, DOI: 10.2174/1568026023393273

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

1. Forbindelse med følgende formel:



15

25

R₆ er alkyl;

30

X er 0; og

$$Z \in \mathbb{N};$$

35

karbamid, karbamyl, karboksyl, thioureid, thiocyanat, sulfonamid, alkyl, alkenyl, alkynyl, alkylloxy, aryl, heteroaryl, sykloalkyl og heterosykloalkyl.

- 5 **2.** Forbindelse ifølge krav 1, hvor hvert av alkyl, alkenyl, alkynyl, sykloalkyl, heterosykloalkyl, aryl, heteroaryl, og alkoksy er usubstituert.
- 3.** Forbindelse ifølge krav 1, hvor R_6 er metyl.
- 10 **4.** Forbindelse ifølge krav 1, hvor hver av R_a og R_b uavhengig av hverandre er H, alkyl eller sykloalkyl.
- 5.** Forbindelse ifølge krav 4, hvor R_a er H og R_b er metyl.
- 15 **6.** Forbindelse ifølge krav 4, hvor hver av R_3 og R_4 er metoksy.
- 7.** Forbindelse ifølge krav 1, hvor forbindelsen er:

20


25

30


35

3

5




10




15

20




25



30

35

5



8. Forbindelsen

10 **9.** Farmasøytisk sammensetning omfattende et stoff fra krav 1 og en farmasøytisk forenelig bærer.

10. Et stoff fra krav 1 brukt til å behandle angiogenesis relaterte lidelser.

15 **11.** Forbindelsen i følge krav 10, hvor den angiogenesis relaterte lidelsen er kreft, aldersrelatert maculaer degenerasjon eller kronisk betennelsessykdom.